Lung cancer drug under the microscope: Real-World study launches

NCT ID NCT07510724

Recruiting now Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Apr 05, 2026 · Last updated Jun 15, 2026 · Updated 10 times

Summary

This study is observing 240 lung cancer patients in Germany and Austria who are receiving the drug tislelizumab as part of their normal care. Researchers want to see how long patients live, how they feel, and what side effects occur. The goal is to learn how well the drug works outside of controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Krankenhaus Nordwest
RECRUITING

Frankfurt am Main, Hesse, 60488, Germany

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Universitätsklinikum St. Pölten - Lilienfeld, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
NOT_YET_RECRUITING

Sankt Pölten, Lower Austria, 3100, Austria

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (DIAGNOSIS) NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC) SMALL CELL LUNG CANCER ( SCLC ) SMALL CELL LUNG CANCER (SCLC)